Mother-to-infant transmission of hepatitis C virus

Yeung, Latifa; King, Susan; Roberts, Eve A.

doi:10.1053/jhep.2001.25885

Cited by 241 publications

(163 citation statements)

References 89 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…In our study, HCV MTCT occurred only among mothers who were HCV-RNA positive (viremic). This is consistent with the findings of other studies [8,27,[36][37][38]. Many but not all studies [36,39] suggest an association between higher concentrations of HCV RNA and a greater risk of MTCT of HCV [38,[40][41][42].…”

Section: Discussionsupporting

confidence: 90%

“…Fewer studies have examined the rates of MTCT of HCV among HIV-coinfected women with well-controlled HIV disease [7]. Acquisition of HCV infection through MTCT has become a major source of pediatric infection [26,27]. Almost all children who remain viremic after several years develop chronic hepatitis [28].…”

mentioning

confidence: 99%

“…The rate of MTCT of HCV is critical for the prediction of HCV disease burden in future generations. Conservative estimates suggest that 10 000 to 60 000 infants may become infected with HCV each year in the world through MTCT of HCV [27]. The purpose of this study was to assess MTCT of HCV among HCV/ HIV-coinfected women enrolled in prospective cohort studies of HIV-infected women in Latin America and the Caribbean with access to HAART.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women

Cabot

Stoszek

Quarleri

et al. 2012

Journal of the Pediatric Infectious Diseases Society

View full text Add to dashboard Cite

Background. Maternal human immunodeficiency virus (HIV) coinfection has been associated with increased hepatitis C virus (HCV) mother-to-child transmission (MTCT). We hypothesized that HCV/HIVcoinfected women with well-controlled HIV disease would not have increased HCV MTCT. Methods. The NISDI Perinatal and LILAC cohorts enrolled HIV-infected pregnant women and their infants in Latin America and the Caribbean. This substudy evaluated the HCV infection status of mothers at participating sites and their live born, singleton infants who had a 6-month postnatal visit by December 31, 2008. Mothers who were anti-HCV-positive, or who had CD4 counts (cells/mm 3 ) <200 with detectable HCV RNA, were considered HCV-infected. All HCV-infected women were tested for HCV RNA. Infants with HCV RNA were considered HCV-infected. Results. Of 1042 enrolled women, 739 (71%) mother-infant pairs met the inclusion criteria. Of the 739 women, 67 (9%) were anti-HCV-positive and 672 anti-HCV-negative [68 (10%) with CD4 counts <200; of these, 3 (4.4%) were HCV RNA-positive]. Therefore, our study population comprised 70 HCV-infected (47 with HCV RNA) and 669 HCV-uninfected women (and their infants). Factors associated with maternal HCV infection included unemployment (odds ratio [OR] = 2.58

show abstract

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women

Cabot

Stoszek

Quarleri

et al. 2012

Journal of the Pediatric Infectious Diseases Society

View full text Add to dashboard Cite

show abstract

“…About 5% of viremic mothers transmit the virus to their offspring (20% with HIV coinfection). 166 High maternal viral load (>600,000 IU/ml), invasive fetal monitoring, prolonged rupture of membranes, and fetal anoxia at the time of delivery are factors that enhance transmission. 85,167 Elective cesarean section is not required for women with HCV infection and breast-feeding does not promote transmission.…”

Section: Hepatitis C In Childrenmentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

“…During the past years vertical infection has become the most important route of viral transmission. [18][19][20] The children are infected in a phase of high immunotolerance. The scarce follow-up data suggest a relatively low disease progression during the first 15 to 20 years of life.…”

mentioning

confidence: 99%

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C

Wirth

Lang²,

Gehring³

et al. 2002

Hepatology

107

View full text Add to dashboard Cite

Treatment with alfa-interferon alone yielded poor results in children with chronic hepatitis C and was not generally recommended. Owing to limited experience with combination therapy in children, the aim of the study was to evaluate the efficacy and tolerability of alfa-interferon 2b in combination with ribavirin in these patients with different routes of viral transmission. In an uncontrolled pilot study, 41 children and adolescents ranging from 3 to 16 years were treated with alfa-interferon at a dose of 3

show abstract

Mother-to-infant transmission of hepatitis C virus

Cited by 241 publications

References 89 publications

Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women

Mother-to-Child Transmission of Hepatitis C Virus (HCV) Among HIV/HCV-Coinfected Women

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C

Contact Info

Product

Resources

About